<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00455767</url>
  </required_header>
  <id_info>
    <org_study_id>DEB-EPIV-201</org_study_id>
    <secondary_id>2006-000756-41 (EUDRACT NR)</secondary_id>
    <nct_id>NCT00455767</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients</brief_title>
  <official_title>Phase IIA Multicenter 1 Week Treatment, Randomised, Double-Blind, Placebo Controlled Study of Depelestat in Patients Suffering From Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to assess safety of Depelestat treatment, as well as efficacy on&#xD;
      prevention and treatment of alveolar inflammation in early pulmonary fibrosis in patients&#xD;
      suffering from persistent Acute Respiratory Distress Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomised, double-blind, parallel groups, placebo-controlled, 1 week&#xD;
      treatment of Depelestat, in patients suffering from persistent ARDS.&#xD;
&#xD;
      Patients admitted in the intensive care unit presenting ARDS criteria persistent for 12 hours&#xD;
      to 24 hours, will be randomly assigned to the treatment by Depelestat or placebo, after a&#xD;
      pre-treatment period as short as possible with a maximum of 48 hours since ARDS criteria are&#xD;
      met. During the pre-treatment period, the informed consent will be obtained from the legally&#xD;
      authorized relative of the patient, and pre-treatment biological and functional examinations&#xD;
      will be performed, particularly blood samples and BAL for biological parameters measurement,&#xD;
      and ventilatory mechanics, for assessment of static compliance of the respiratory system.&#xD;
&#xD;
      After the pre-treatment period, the patient will receive treatment by Depelestat or placebo&#xD;
      during 7 days, or until extubation of the patient if this occurs before 7 days of treatment.&#xD;
      During this treatment period, the patient will be submitted to a daily measurement of static&#xD;
      compliance of the respiratory system, as long as the patient adaptation to 24 hours after&#xD;
      mechanical ventilation allows the procedure, and at 96 initiation of treatment, to a blood&#xD;
      sampling and a bronchoalveolar lavage for several biological parameters assessment.&#xD;
&#xD;
      On the first and last day of administration, blood will be also collected for pharmacokinetic&#xD;
      evaluation.&#xD;
&#xD;
      During the post-treatment period, the patient will be submitted, at 48 h ± 24 h after the end&#xD;
      of treatment, to a blood sampling and a BAL (this BAL is not performed when contraindication&#xD;
      criteria are present, if the patient is already extubated, and in case of planed extubation&#xD;
      during the subsequent 24 hours) for several biological parameters assessment, and a daily&#xD;
      measurement of static compliance as long as the patient adaptation to mechanical ventilation&#xD;
      allows the procedure. Patients already extubated will not be submitted to BAL nor to static&#xD;
      compliance measurements.&#xD;
&#xD;
      After the end of the treatment, patients will be followed daily for 28 days after the&#xD;
      diagnostic of ARDS, or until death whichever occurred first.&#xD;
&#xD;
      The duration of the study for each survivor patient will be 28 days. Survivors to day 28 will&#xD;
      be contacted monthly to assess survival and fill in a QOL questionnaire on days 60 and 90.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Static compliance relative change from pre-treatment to last on treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCPIII and cytokines concentration, as well as neutrophil influx relative change in BAL fluid from pre-treatment to post-treatment</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Fibrosis</condition>
  <condition>Lung Disease</condition>
  <condition>Respiratory Disorders</condition>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Depelestat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-hNE4</intervention_name>
    <description>I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from persistent ARDS as defined by the American and European&#xD;
             Consensus Conference on ARDS, 1994&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ARDS secondary to traumatism&#xD;
&#xD;
          -  Pulmonary emphysema on pulmonary fibrosis&#xD;
&#xD;
          -  Lung pneumocystosis&#xD;
&#xD;
          -  Bronchopleural fistula&#xD;
&#xD;
          -  Systemic corticosteroid treatment for more than 2 weeks before inclusion&#xD;
&#xD;
          -  Severe organ disease excepted renal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Saudubray, MD</last_name>
    <role>Study Director</role>
    <affiliation>Debiopharm SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alain Mercat</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yves Castaing</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurent Brochard</name>
      <address>
        <city>Créteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-François Timsit</name>
      <address>
        <city>Grenoble Cedex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Claude Guerin</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samir Jaber</name>
      <address>
        <city>Montpellier Cedex 05</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Yves Fagon</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Daniel Chiche</name>
      <address>
        <city>Paris Cedex</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Jacques Rouby</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Christophe Richard</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean-Michel Arnal</name>
      <address>
        <city>Toulon</city>
        <zip>83100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massimo Antonelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jordi Mancebo D.</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fekri Abroug</name>
      <address>
        <city>Monastir</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Tunisia</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Honoré S, Attalah HL, Azoulay E, Soussy CJ, Saudubray F, Harf A, Brochard L, Delclaux C. Beneficial effect of an inhibitor of leukocyte elastase (EPI-hNE-4) in presence of repeated lung injuries. Shock. 2004 Aug;22(2):131-6.</citation>
    <PMID>15257085</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>March 14, 2007</study_first_submitted>
  <study_first_submitted_qc>April 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <last_update_submitted>June 23, 2008</last_update_submitted>
  <last_update_submitted_qc>June 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>François Saudubray, M.D.</name_title>
    <organization>Debiopharm S.A.</organization>
  </responsible_party>
  <keyword>persistent ARDS</keyword>
  <keyword>alveolar inflammation</keyword>
  <keyword>early pulmonary fibrosis</keyword>
  <keyword>mechanichal ventilation</keyword>
  <keyword>P/V curve</keyword>
  <keyword>Static compliance</keyword>
  <keyword>elastase activity</keyword>
  <keyword>inhibitor of Human Neutrophil Elastase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

